FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2117355364> ?p ?o ?g. }

• W2117355364 endingPage "1505" @default.
• W2117355364 startingPage "1493" @default.
• W2117355364 abstract "Background The combination of an anti-VEGF or an anti-EGFR-targeted monoclonal antibody with chemotherapy has shown clinical activity in patients with metastatic colorectal cancer. However, combining both anti-VEGF and anti-EGFR antibodies with chemotherapy in first-line treatment resulted in adverse outcomes. We assessed whether the combination of erlotinib, an EGFR tyrosine kinase inhibitor, with bevacizumab could increase the efficacy of maintenance therapy in patients with unresectable metastatic colorectal cancer. Methods This randomised, open-label, phase 3 study was undertaken in 49 centres in France, Austria, and Canada. Eligible patients were aged 18–80 years with histologically confirmed, unresectable metastatic colorectal cancer, WHO performance status 0–2, had received no previous therapy for metastatic disease, and had adequate organ function. Patients without disease progression after bevacizumab-based induction therapy were randomly assigned (1:1) by a minimisation technique to bevacizumab (7·5 mg/kg every 3 weeks) or bevacizumab plus erlotinib (150 mg once daily) as maintenance therapy until progression. All patients were stratified by centre, baseline performance status, age, and number of metastatic sites. The primary endpoint was progression-free survival on maintenance therapy analysed by intention to treat. We report the final analysis. This trial is registered with ClinicalTrials.gov, number NCT00265824. Findings Between Jan 1, 2007, and Oct 13, 2011, 700 eligible patients were enrolled; following induction treatment, patients without disease progression were randomly assigned to bevacizumab (n=228) or bevacizumab plus erlotinib (n=224). At the final analysis, median follow-up was 51·0 months (IQR 36·0–60·0) in the bevacizumab group and 48·3 months (31·5–61·0) in the bevacizumab plus erlotinib group. In the primary analysis (after 231 progression-free survival events), median progression-free survival from randomisation was 5·1 months (95% CI 4·1–5·9) in the bevacizumab plus erlotinib group compared with 6·0 months (4·6–7·9) in the bevacizumab group (stratified hazard ratio [HR] 0·79 [95% CI 0·60–1·06]; p=0·11; unstratified HR 0·76 [0·59–0·99]; p=0·043). In the final analysis, median progression-free survival from randomisation was 5·4 months (95% CI 4·3–6·2) in the bevacizumab plus erlotinib group compared with 4·9 months (4·1–5·7) in the bevacizumab group (stratified HR 0·81 [95% CI 0·66–1·01], p=0·059; unstratified HR 0·78 [0·68–0·96], p=0·019). At the final analysis, median overall survival from maintenance was 24·9 months (95% CI 21·4–28·9) in the bevacizumab plus erlotinib group and 22·1 months (19·6–26·7) in the bevacizumab group (stratified HR 0·79 [95% CI 0·63–0·99], p=0·036; unstratified HR 0·79 [0·64–0·98], p=0·035). The most frequent grade 3–4 adverse events were skin rash (47 [21%] of 220 patients in the bevacizumab plus erlotinib group vs none of 224 patients in the bevacizumab alone group), diarrhoea (21 [10%] vs two [<1%]), and asthenia (12 [5%] vs two [<1%]). Interpretation Maintenance bevacizumab plus erlotinib might be a new non-chemotherapy-based maintenance option for the first-line treatment of patients with unresectable metastatic colorectal cancer after bevacizumab-based induction therapy. Funding GERCOR and F Hoffmann-La Roche. The combination of an anti-VEGF or an anti-EGFR-targeted monoclonal antibody with chemotherapy has shown clinical activity in patients with metastatic colorectal cancer. However, combining both anti-VEGF and anti-EGFR antibodies with chemotherapy in first-line treatment resulted in adverse outcomes. We assessed whether the combination of erlotinib, an EGFR tyrosine kinase inhibitor, with bevacizumab could increase the efficacy of maintenance therapy in patients with unresectable metastatic colorectal cancer. This randomised, open-label, phase 3 study was undertaken in 49 centres in France, Austria, and Canada. Eligible patients were aged 18–80 years with histologically confirmed, unresectable metastatic colorectal cancer, WHO performance status 0–2, had received no previous therapy for metastatic disease, and had adequate organ function. Patients without disease progression after bevacizumab-based induction therapy were randomly assigned (1:1) by a minimisation technique to bevacizumab (7·5 mg/kg every 3 weeks) or bevacizumab plus erlotinib (150 mg once daily) as maintenance therapy until progression. All patients were stratified by centre, baseline performance status, age, and number of metastatic sites. The primary endpoint was progression-free survival on maintenance therapy analysed by intention to treat. We report the final analysis. This trial is registered with ClinicalTrials.gov, number NCT00265824. Between Jan 1, 2007, and Oct 13, 2011, 700 eligible patients were enrolled; following induction treatment, patients without disease progression were randomly assigned to bevacizumab (n=228) or bevacizumab plus erlotinib (n=224). At the final analysis, median follow-up was 51·0 months (IQR 36·0–60·0) in the bevacizumab group and 48·3 months (31·5–61·0) in the bevacizumab plus erlotinib group. In the primary analysis (after 231 progression-free survival events), median progression-free survival from randomisation was 5·1 months (95% CI 4·1–5·9) in the bevacizumab plus erlotinib group compared with 6·0 months (4·6–7·9) in the bevacizumab group (stratified hazard ratio [HR] 0·79 [95% CI 0·60–1·06]; p=0·11; unstratified HR 0·76 [0·59–0·99]; p=0·043). In the final analysis, median progression-free survival from randomisation was 5·4 months (95% CI 4·3–6·2) in the bevacizumab plus erlotinib group compared with 4·9 months (4·1–5·7) in the bevacizumab group (stratified HR 0·81 [95% CI 0·66–1·01], p=0·059; unstratified HR 0·78 [0·68–0·96], p=0·019). At the final analysis, median overall survival from maintenance was 24·9 months (95% CI 21·4–28·9) in the bevacizumab plus erlotinib group and 22·1 months (19·6–26·7) in the bevacizumab group (stratified HR 0·79 [95% CI 0·63–0·99], p=0·036; unstratified HR 0·79 [0·64–0·98], p=0·035). The most frequent grade 3–4 adverse events were skin rash (47 [21%] of 220 patients in the bevacizumab plus erlotinib group vs none of 224 patients in the bevacizumab alone group), diarrhoea (21 [10%] vs two [<1%]), and asthenia (12 [5%] vs two [<1%]). Maintenance bevacizumab plus erlotinib might be a new non-chemotherapy-based maintenance option for the first-line treatment of patients with unresectable metastatic colorectal cancer after bevacizumab-based induction therapy." @default.
• W2117355364 created "2016-06-24" @default.
• W2117355364 creator A5002063921 @default.
• W2117355364 creator A5002926775 @default.
• W2117355364 creator A5007810585 @default.
• W2117355364 creator A5008863246 @default.
• W2117355364 creator A5013525685 @default.
• W2117355364 creator A5014323516 @default.
• W2117355364 creator A5016773298 @default.
• W2117355364 creator A5019536561 @default.
• W2117355364 creator A5020893157 @default.
• W2117355364 creator A5026643846 @default.
• W2117355364 creator A5028514396 @default.
• W2117355364 creator A5052788938 @default.
• W2117355364 creator A5054670872 @default.
• W2117355364 creator A5056150288 @default.
• W2117355364 creator A5064556770 @default.
• W2117355364 creator A5069111171 @default.
• W2117355364 creator A5074775103 @default.
• W2117355364 creator A5084470537 @default.
• W2117355364 creator A5085315048 @default.
• W2117355364 creator A5086706783 @default.
• W2117355364 creator A5086894589 @default.
• W2117355364 date "2015-11-01" @default.
• W2117355364 modified "2023-10-01" @default.
• W2117355364 title "Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial" @default.
• W2117355364 cites W1993780950 @default.
• W2117355364 cites W2002226820 @default.
• W2117355364 cites W2005348280 @default.
• W2117355364 cites W2006709656 @default.
• W2117355364 cites W2013335792 @default.
• W2117355364 cites W2085633477 @default.
• W2117355364 cites W2095201384 @default.
• W2117355364 cites W2108373675 @default.
• W2117355364 cites W2109498035 @default.
• W2117355364 cites W2111031611 @default.
• W2117355364 cites W2115735904 @default.
• W2117355364 cites W2118117088 @default.
• W2117355364 cites W2121368761 @default.
• W2117355364 cites W2122152991 @default.
• W2117355364 cites W2124440635 @default.
• W2117355364 cites W2124451268 @default.
• W2117355364 cites W2127640925 @default.
• W2117355364 cites W2127941773 @default.
• W2117355364 cites W2128447158 @default.
• W2117355364 cites W2136601558 @default.
• W2117355364 cites W2137417501 @default.
• W2117355364 cites W2144690940 @default.
• W2117355364 cites W2152259586 @default.
• W2117355364 cites W2153211112 @default.
• W2117355364 cites W2156229277 @default.
• W2117355364 cites W2160373161 @default.
• W2117355364 cites W2161133634 @default.
• W2117355364 cites W2162896805 @default.
• W2117355364 cites W2168579528 @default.
• W2117355364 cites W2171406886 @default.
• W2117355364 cites W2246448301 @default.
• W2117355364 cites W2341036513 @default.
• W2117355364 doi "https://doi.org/10.1016/s1470-2045(15)00216-8" @default.
• W2117355364 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26474518" @default.
• W2117355364 hasPublicationYear "2015" @default.
• W2117355364 type Work @default.
• W2117355364 sameAs 2117355364 @default.
• W2117355364 citedByCount "98" @default.
• W2117355364 countsByYear W21173553642015 @default.
• W2117355364 countsByYear W21173553642016 @default.
• W2117355364 countsByYear W21173553642017 @default.
• W2117355364 countsByYear W21173553642018 @default.
• W2117355364 countsByYear W21173553642019 @default.
• W2117355364 countsByYear W21173553642020 @default.
• W2117355364 countsByYear W21173553642021 @default.
• W2117355364 countsByYear W21173553642022 @default.
• W2117355364 countsByYear W21173553642023 @default.
• W2117355364 crossrefType "journal-article" @default.
• W2117355364 hasAuthorship W2117355364A5002063921 @default.
• W2117355364 hasAuthorship W2117355364A5002926775 @default.
• W2117355364 hasAuthorship W2117355364A5007810585 @default.
• W2117355364 hasAuthorship W2117355364A5008863246 @default.
• W2117355364 hasAuthorship W2117355364A5013525685 @default.
• W2117355364 hasAuthorship W2117355364A5014323516 @default.
• W2117355364 hasAuthorship W2117355364A5016773298 @default.
• W2117355364 hasAuthorship W2117355364A5019536561 @default.
• W2117355364 hasAuthorship W2117355364A5020893157 @default.
• W2117355364 hasAuthorship W2117355364A5026643846 @default.
• W2117355364 hasAuthorship W2117355364A5028514396 @default.
• W2117355364 hasAuthorship W2117355364A5052788938 @default.
• W2117355364 hasAuthorship W2117355364A5054670872 @default.
• W2117355364 hasAuthorship W2117355364A5056150288 @default.
• W2117355364 hasAuthorship W2117355364A5064556770 @default.
• W2117355364 hasAuthorship W2117355364A5069111171 @default.
• W2117355364 hasAuthorship W2117355364A5074775103 @default.
• W2117355364 hasAuthorship W2117355364A5084470537 @default.
• W2117355364 hasAuthorship W2117355364A5085315048 @default.
• W2117355364 hasAuthorship W2117355364A5086706783 @default.
• W2117355364 hasAuthorship W2117355364A5086894589 @default.
• W2117355364 hasConcept C121608353 @default.
• W2117355364 hasConcept C126322002 @default.
• W2117355364 hasConcept C141071460 @default.

• next